

617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: MRD and Novel molecular Markers

[Watch Session](#)

272 [The Impact of Sorafenib on Phospho-FLT3 Inhibition and *FLT3*-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with *FLT3*-ITD Acute Myeloid Leukemia \(ALLG AMLM16\)](#)

Natasha S Anstee, Giovanna Pomilio, Mark Levis, et al.

273 [Molecular Predictors and Effectiveness of Measurable Residual Disease \(MRD\) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia](#)

Maximilian Stahl, Andriy Derkach, Christopher Famulare, et al.

274 [Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts](#)

Rhonda E. Ries, Timothy Junius Triche Jr., Jenny L. Smith, et al.

275 [Next-Generation Sequencing \(NGS\)-Based Measurable Residual Disease \(MRD\) Monitoring in Acute Myeloid Leukemia with *FLT3* Internal Tandem Duplication \(*FLT3*-ITD[±] AML\) Treated with Additional Midostaurin](#)

Julia K. Herzig, Frank G. Rücker, Laura K. Schmalbrock, et al.

276 [Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia](#)

Abhishek Maiti, Courtney D. DiNardo, Sa A Wang, et al.

277 [The Natural History of *NPM1*^{MUT} Measurable Residual Disease \(MRD\) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia \(AML\)](#)

Ing Soo Tiong, Richard Dillon, Adam Ivey, et al.